Samchundang Pharm announced on April 6 that CEO Jeon Inseok has withdrawn the plan for a block deal of shares worth 250 billion won, which was disclosed on March 24.


Samchundang Pharm CEO Jeon Inseok Withdraws 250 Billion Won Block Deal Plan View original image

CEO Jeon cited the spread of market distrust and the damage to shareholder value as reasons for canceling the block deal. The share sale was originally intended to cover tax payments such as gift taxes. However, suspicions emerged in the market that the company had exaggerated the size of its U.S. supply contract to facilitate the block deal.


CEO Jeon stated, "There was absolutely no fabrication or exaggeration regarding the contract details, but as negative suspicions continued to be raised and shareholders were being harmed, I could not stand by as CEO. I decided to withdraw the block deal, believing that protecting the company's fundamental value should take precedence over fulfilling my personal financial obligations."


CEO Jeon is scheduled to hold a press briefing later this afternoon to provide a detailed explanation of the circumstances behind the block deal cancellation, address suspicions related to the independent platform 'S-PASS,' and clarify the nature of the U.S. contract.



He added, "The most urgent task is to restore market trust through business performance," and continued, "I will prove the company's value with specific figures and results for the milestones scheduled in the second half of the year and seek a revaluation of our corporate value."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing